StephenE.GitelmanMD

Pediatric Endocrinology • San Francisco, CA

Clinical Professor of Pediatrics, UCSF

Join to view full profile

Dr. Gitelman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gitelman's full profile

Already have an account?

Office
513 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-476-3748

Fax+1 415-476-8214

Education & Training

University of California (San Francisco)Fellowship, Pediatric Cardiology, 1987 - 1990
University of California (San Francisco)Residency, Pediatrics, 1984 - 1987
University of North Carolina at Chapel Hill School of MedicineClass of 1984

Certifications & Licensure

CA State Medical License 1986 - 2026
American Board of Pediatrics Pediatric Endocrinology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com

Clinical Trials

TrialNet Pathway to Prevention of T1D Start of enrollment: 2004 Feb 01
Recruiting
Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus Start of enrollment: 2004 Aug 01
Completed
Not Applicable
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus Start of enrollment: 2007 Feb 01
Completed
Phase 3
Study of Antithymocyte Globulin for Treatment of New-onset T1DM Start of enrollment: 2007 Aug 01
Terminated
Phase 2
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" Start of enrollment: 2010 Aug 01
Completed
Phase 2
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs Start of enrollment: 2010 Nov 01
Completed
Phase 1
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Start of enrollment: 2013 Mar 01
Completed
Phase 2
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus Start of enrollment: 2014 Jan 01
Completed
Phase 2
Type 1 Diabetes Extension Study Start of enrollment: 2016 Aug 18
Recruiting
T1DM Immunotherapy Using Polyclonal Tregs + IL-2 Start of enrollment: 2016 Aug 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

243 citations
Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
Carla J. Greenbaum, Craig A. Beam, David Boulware, Stephen E. Gitelman, Peter A. Gottlieb
Diabetes. 2012-08-01
840 citations
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
Kevan C. Herold, William Hagopian, Julie A. Auger, Ena Poumian-Ruiz, Lesley Taylor
The New England Journal of Medicine. 2002-05-30
724 citations
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch, Stephen E. Gitelman, Shipra Gupta
Science Translational Medicine. 2015-11-25

Press Mentions

UCSF Researchers Working on Approval of Breakthrough Diabetes TherapyDecember 21st, 2022
Cancer Drug May Slow Course of Type-1 DiabetesJuly 19th, 2021
Immunotherapy Delays Type 1 Diabetes Onset in People at High RiskJune 9th, 2019
Join now to see all

Grant Support

K12 In Diabetes (KIDS)National Institute Of Diabetes And Digestive And Kidney Diseases2011
UCSF Trialnet: A Phase II Trial Of Imatimib In New Onset Type I DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
UCSF Trialnet: A Phase II Trial Of Hokt3gamma1 (Ala-Ala)National Institute Of Diabetes And Digestive And Kidney Diseases2001–2007
Trialnet Natural History Study Of The Development Of Type 1 DiabetesNational Center For Research Resources2005
The Type 1 Diabetes Genetics Consortium ProtocolNational Center For Research Resources2005
Pilot Study On The Effect Of Oral Alpha-Lipoic Acid On Oxidative Stress In T1dmNational Center For Research Resources2005
Immune Tolerance Network Pilot 2 Protocol NO Lpl12National Center For Research Resources2005
Use Of Continuous Glucose Monitoring In Infants And Children With HypoglycemiaNational Center For Research Resources2004–2005
T Cell Assays In Type 1 Diabetes MellitusNational Center For Research Resources2004–2005
Hoktt3yl (Ala Ala) In Participants With Type 1 Diabetes MellitusNational Center For Research Resources2004–2005
A Multicenter, Randomized Double Blind Trial Of Metformin In Obese AdolescentsNational Center For Research Resources2004–2005
Measurement Of Insulin Secretory Response To A Mixed Meal In Normal IndividualsNational Center For Research Resources2004
Immune Tolerance Network Pilot 2 Protocol NO. Lpl12National Center For Research Resources2004
CRF In The Diagnosis And Longterm Management Of Pediatric Cushing'S DiseaseNational Center For Research Resources1998–2002
Vgr-1/Bmp-6 And Chondrogenesis And OsteogenesisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1994–1997
CRF In Diagnosis And Long Term Management Of Pediatric Cushing'S DiseaseNational Center For Research Resources1996
CRF In Diagnosis And Management Of Pediatric Cushing'S DiseaseNational Center For Research Resources1995
Role Of Vgr-1/Bmp-6 In Chondrogenesis And OsteogenesisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1993
Transcriptional Regulation Of P450 C17 GeneNational Institute Of Diabetes And Digestive And Kidney Diseases1989

StephenE.GitelmanMD

Dr. Gitelman is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.